Relationship between IL-10 and tumor markers in breast cancer patients
Tóm tắt
Từ khóa
Tài liệu tham khảo
Esteva, 2004, Prognostic molecular markers in early breast cancer, Breast Cancer Res, 6, 109, 10.1186/bcr777
Yamashita, 2004, Coexistence of Her2 over-expression and p53 protein accumulation is a strong prognostic molecular marker in breast cancer, Breast Cancer Res, 6, R24, 10.1186/bcr738
Wong, 1998, Functional analysis of tumor-infiltrating leukocytes in breast cancer patients, J Surg Res, 76, 95, 10.1006/jsre.1998.5301
Venetsanakos, 1997, High incidence of interleukin 10 mRNA but not interleukin 2 mRNA detected in human breast tumours, Br J Cancer, 75, 1826, 10.1038/bjc.1997.311
Huang, 1995, Human non-small cell lung cancer cells express a type 2 cytokine pattern, Cancer Res, 55, 3847
Green, 1997, Expression of cytokine messenger RNA in normal and neoplastic human breast tissue: identification of interleukin-8 as a potential regulatory factor in breast tumours, Int J Cancer, 72, 937, 10.1002/(SICI)1097-0215(19970917)72:6<937::AID-IJC3>3.0.CO;2-Q
Marrogi, 1997, Study of tumor infiltrating lymphocytes and transforming growth factor-beta as prognostic factor in breast carcinoma, Int J Cancer, 74, 492, 10.1002/(SICI)1097-0215(19971021)74:5<492::AID-IJC3>3.0.CO;2-Z
Fiorentino, 1991, IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells, J Immunol, 146, 3444, 10.4049/jimmunol.146.10.3444
Cohen, 1997, Interleukin-10 rescues T cells from apoptotic cell death: association with an upregulation of Bcl-2, Immunology, 92, 1, 10.1046/j.1365-2567.1997.00348.x
Taga, 1993, IL-10 inhibits apoptotic cell death in human T cells starved of IL-2, Int Immunol, 5, 1599, 10.1093/intimm/5.12.1599
Alas, 2001, Cancer Res, 61, 5137
Wang, 2004, Effects of platelet-derived growth factor and interleukin-10 on Fas/Fas-ligand and Bcl-2/Bax mRNA expression in rat hepatic stellate cells in vitro, World J Gastroenterol, 10, 2706, 10.3748/wjg.v10.i18.2706
Okuda, 2003, Regulatory role of p53 in experimental autoimmune encephalomyelitis, J Neuroimmunol, 135, 29, 10.1016/S0165-5728(02)00428-9
Ohkuso-Tsukada, 1999, Accelerated development and aging of the immune system in p53-deficient mice, J Immunol, 163, 1966, 10.4049/jimmunol.163.4.1966
Coppola, 1999, Pathology update significance of p53 and Bcl-2 protein expression in human breast ductal carcinoma, Cancer Control, 6, 181, 10.1177/107327489900600211
Megha, 2002, p53 mutation in breast cancer. Correlation with cell kinetics and cell of origin, J Clin Pathol, 55, 461, 10.1136/jcp.55.6.461
Ellis, 2004, Overcoming endocrine therapy resistance by signal transduction inhibition, Oncologist, 9, 20, 10.1634/theoncologist.9-suppl_3-20
Sjostrom, 2002, The predictive value of bcl-2, bax, bcl-xL, bag-1, fas, and fasL for chemotherapy response in advanced breast cancer, Clin Cancer Res, 8, 811
Osin PP, Lakhani SR. The pathology of familial breast cancer: immunohistochemistry and molecular analysis [review]. http://breast-cancer-research.com/vol1no1/27oct99/review/3
Yang, 2000, Expression of Bcl-2 but not Bax or p53 correlates with in vitro resistance to a series of anticancer drugs in breast carcinoma, Breast Cancer Res Treat, 61, 211, 10.1023/A:1006474307180
Martinez-Arribas, 2003, Immunofluorometric study of Bcl-2 and Bax expression in clinical fresh tumor samples from breast cancer patients, Anticancer Res, 23, 565
Tsutsui, 2003, Prognostic significance of the coexpression of p53 protein and c-erbB2 in breast cancer, Am J Surg, 185, 165, 10.1016/S0002-9610(02)01203-5
Navarro-Gómez, 1999, Gene therapy for carcinoma of the breast pro-apoptotic gene therapy, Breast Cancer Res, 2, 32, 10.1186/bcr27
Halak, 1999, Tumor-induced interleukin-10 inhibits type 1 immune responses directed at a tumor antigen as well as a non-tumor antigen present at the tumor site, Cancer Res, 59, 911
Beissert, 1995, IL-10 inhibits tumor antigen presentation by epidermal antigen-presenting cells, J Immunol, 154, 1280, 10.4049/jimmunol.154.3.1280
Toomey, 1999, Phenotyping of immune cell infiltrates in breast and colorectal tumours, Immunol Invest, 28, 29, 10.3109/08820139909022721
Becker, 1993, Tumour mechanisms from immunosurveillance: induction of unresponsiveness in a specific MNC-restricted CD4+ human T cell clone by the autologous MHC class II+ melanoma, Int Immunol, 5, 1501, 10.1093/intimm/5.12.1501
Reed, 1996, Bcl-2 family proteins: regulators of cell death involved in pathogenesis of cancer and resistance to therapy, J Chem Biochem, 60, 23
Hashimoto, 2001, IL-10 inhibits granulocyte macrophage colony-stimulating factor dependent human monocyte survival at the early stage of the culture and inhibits the generation of macrophages, J Immunol, 167, 3619, 10.4049/jimmunol.167.7.3619
Alas, 2001, Inhibition of interleukin 10 by rituximab results in down-regulation of Bcl-2 and sensitization of B-cell Non-Hodgkin's Lymphoma to apoptosis, Clin Cancer Res, 7, 709
Amirghofran, 2004, Apoptosis in transitional cell carcinoma of bladder and its relation to proliferation and expression of p53 and Bcl-2, Pathol Oncol Res, 10, 154, 10.1007/BF03033744
Fox, 2002, Germ-line p53-targeted disruption inhibits helicobacter-induced premalignant lesions and invasive gastric carcinoma through down-regulation of Th1 proinflammatory responses, Cancer Res, 62, 696
Parajuli, 2001, Immunization with wild-type p53 gene sequences coadministered with Flt3 ligand induces an antigen-specific type 1 T-cell response, Cancer Res, 61, 8227